Methotrexate Cipla (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a key co‑factor in DNA, RNA and protein synthesis. By limiting these building blocks, the drug suppresses the proliferation of immune cells in arthritis and psoriasis and interferes with tumor cell replication in cancer.

The dose of Methotrexate Cipla is individualized and set by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Dosage regimens may differ between weekly low‑dose therapy for arthritis and higher, cyclic dosing for oncologic protocols.

Methotrexate is generally contraindicated during pregnancy because of its known teratogenic potential. Women of childbearing potential should use effective contraception while on therapy. Limited data exist for breastfeeding; most guidelines advise against use during lactation due to possible infant exposure.

To order Methotrexate Cipla, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

For rheumatoid arthritis, methotrexate is often the first‑line conventional disease‑modifying antirheumatic drug (DMARD) and is less expensive than biologic agents such as TNF‑α inhibitors. In oncology, it may be used alone or in combination regimens, offering a different toxicity profile compared with newer targeted therapies.

Methotrexate Cipla tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Methotrexate Cipla is administered orally, usually with a full glass of water. For certain indications, clinicians may advise taking the dose on an empty stomach or with folic acid supplementation to reduce gastrointestinal irritation. The exact schedule is determined by the prescriber.

Serious adverse events include severe liver toxicity, interstitial pneumonitis, and bone‑marrow suppression leading to pancytopenia. Patients should promptly report persistent abdominal pain, jaundice, unexplained cough or shortness of breath, and signs of infection such as fever or sore throat.

Methotrexate Cipla should be avoided in patients with known hypersensitivity to methotrexate, severe liver disease, significant renal impairment, active infections, or in women who are pregnant or planning pregnancy without reliable contraception. It is also contraindicated in individuals receiving other potent folate antagonists.